<DOC>
	<DOCNO>NCT00332007</DOCNO>
	<brief_summary>Overall trial objective : 1 . Can treatment tonabersat reduce number day aura and/or migraine headache patient migraine aura 2 . How well tolerated treatment tonabersat The study base hypothesis unique mechanism action tonabersat inhibit early event generation aura migraine headache effective prophylactic treatment</brief_summary>
	<brief_title>Tonabersat Prophylaxis Migraine With Aura</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<criteria>Patients establish history migraine least one year meeting diagnostic criterion International Classification Headache Disorders Edition 2 ( Appendix 2 ) experience least one aura month . Male female patient 1865 year age Women child bear potential must use reliable form contraception ( define protocol ) least 3 month prior enrolment must negative pregnancy test screen intention become pregnant study period Patients experience headache migraine tension headache Overuse acute migraine treatment define 14 daily dos per month analgesic 9 daily dos per month ergot triptans within last two month Migraine prophylactic treatment within two month prior entry trial Patients take following medication migraine : betablockers , tricyclic antidepressant ( last 2 month ) , antiepileptic dug ( last 2 month ) , calcium channel blocker , monoamine oxidase inhibitor , daily NSAIDs , daily paracetamol , high dose magnesium supplement ( 600mg/day ) . Parenteral administration botulinum toxin also exclude . These drug permit give disease migraine provide , opinion investigator dose keep constant throughout trial . Patients , opinion investigator , significant cerebrovascular disease e.g . transient ischaemic attack , stroke Patients , opinion investigator , clinically significant cardiovascular disease Patients suffer current clinical diagnosis major depressive disorder schizophrenia Patients renal dysfunction , define serum creatinine great 125 % upper limit normal age group Patients hepatic dysfunction define liver function test ( AST , ALT , alkaline phosphatase , bilirubin ) great twice upper limit normal age group Patients know alcohol substance abuse Use investigational drug ( indication ) within 30 day 5 halflives , whichever longer , prior screen Women pregnant breast feed Women childbearing potential use reliable form contraception Patients clinically significant condition , investigator opinion , would render unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>